H Pylori Guideline Revision Supplement 2022: Difference between revisions
From Guide to YKHC Medical Practices
mNo edit summary |
mNo edit summary |
||
| Line 15: | Line 15: | ||
==Results== | ==Results== | ||
# ANMC H. Pylori Treatment Guideline has no significant changes pertinent to the YKHC guideline. Of note, ANMC has started a study of offering EGD for gastric cancer screening for patients with a first-degree relative (parent, sibling, or child) with gastric cancer; they are treating to eradicate H. pylori in this group regardless of findings; but this treatment is limited to the study patients. | # ANMC H. Pylori Treatment Guideline has no significant changes pertinent to the YKHC guideline. Of note, ANMC has started a study of offering EGD for gastric cancer screening for patients with a first-degree relative (parent, sibling, or child) with gastric cancer; they are treating to eradicate H. pylori in this group regardless of findings; but this treatment is limited to the study patients and thus is not applicable to our practice in Bethel. | ||
# PubMed search returned 49 articles. The only article published since the prior literature search (in 2017) to address treatment in our setting was the CDC conference summary,<ref name="Nolen2020"/> which continues to explicitly advocate the current algorithm/guideline. | # PubMed search returned 49 articles. The only article published since the prior literature search (in 2017) to address treatment in our setting was the CDC conference summary,<ref name="Nolen2020"/> which continues to explicitly advocate the current algorithm/guideline. | ||
<br> | <br> | ||
==Guideline Changes== | ==Guideline Changes== | ||
#Under treatment indications, "Intestinal Metaplasia" is changed to "Gastric Intestinal Metaplasia" to prevent any confusion with Barrett's esophagus. | #Under treatment indications, "Intestinal Metaplasia" is changed to "Gastric Intestinal Metaplasia" (to prevent any confusion with Barrett's esophagus). | ||
#Addition of box specifying test of cure details. | #Addition of box specifying test of cure details. | ||
<br> | <br> | ||
Revision as of 01:25, 13 January 2022
Reason[s] for update
Routine 2-year update.
Methods
- Review of latest ANMC H. pylori treatment guideline (Feb 19, 2020 , Archive)
- Updated literature search (PubMed, (alaska[Title] OR polar[Title] OR arctic[Title]) AND helicobacter[Title/Abstract]). This is a broader search than previously in that it looks for "helicobacter" in the abstract as well as the title.
- Attendance at the 2019 Combating Gastric Cancer in Alaska Native People: An Expert and Community Symposium
- >Hosted by the CDC in Anchorage, Alaska
- >Experts were longstanding, world-renown researchers
- >Results were published in Gastroenterology in April 2020[1]
Results
- ANMC H. Pylori Treatment Guideline has no significant changes pertinent to the YKHC guideline. Of note, ANMC has started a study of offering EGD for gastric cancer screening for patients with a first-degree relative (parent, sibling, or child) with gastric cancer; they are treating to eradicate H. pylori in this group regardless of findings; but this treatment is limited to the study patients and thus is not applicable to our practice in Bethel.
- PubMed search returned 49 articles. The only article published since the prior literature search (in 2017) to address treatment in our setting was the CDC conference summary,[1] which continues to explicitly advocate the current algorithm/guideline.
Guideline Changes
- Under treatment indications, "Intestinal Metaplasia" is changed to "Gastric Intestinal Metaplasia" (to prevent any confusion with Barrett's esophagus).
- Addition of box specifying test of cure details.
Author: Andrew W. Swartz, MD
References
- ↑ 1.0 1.1 Nolen LD, Vindigni SM, Parsonnet J; Symposium leaders. Combating Gastric Cancer in Alaska Native People: An Expert and Community Symposium. Gastroenterology. 2020 Apr;158(5):1197-1201. doi: 10.1053/j.gastro.2019.11.299. PMID: 31836529; PMCID: PMC7103478. DOI:10.1053/j.gastro.2019.11.299
